JPWO2021152201A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2021152201A5 JPWO2021152201A5 JP2022542038A JP2022542038A JPWO2021152201A5 JP WO2021152201 A5 JPWO2021152201 A5 JP WO2021152201A5 JP 2022542038 A JP2022542038 A JP 2022542038A JP 2022542038 A JP2022542038 A JP 2022542038A JP WO2021152201 A5 JPWO2021152201 A5 JP WO2021152201A5
- Authority
- JP
- Japan
- Prior art keywords
- formula
- compound
- integer
- diseases
- values
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 claims 32
- 230000007170 pathology Effects 0.000 claims 22
- 150000003839 salts Chemical class 0.000 claims 16
- 150000002148 esters Chemical class 0.000 claims 14
- 201000010099 disease Diseases 0.000 claims 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 10
- 239000000203 mixture Substances 0.000 claims 9
- 235000016709 nutrition Nutrition 0.000 claims 9
- 206010028980 Neoplasm Diseases 0.000 claims 8
- 239000003814 drug Substances 0.000 claims 8
- 210000005036 nerve Anatomy 0.000 claims 8
- 238000002360 preparation method Methods 0.000 claims 8
- 230000002265 prevention Effects 0.000 claims 8
- 230000008929 regeneration Effects 0.000 claims 8
- 238000011069 regeneration method Methods 0.000 claims 8
- 238000011282 treatment Methods 0.000 claims 8
- 238000000338 in vitro Methods 0.000 claims 7
- 208000012902 Nervous system disease Diseases 0.000 claims 6
- 208000025966 Neurological disease Diseases 0.000 claims 6
- 206010033799 Paralysis Diseases 0.000 claims 6
- 230000006698 induction Effects 0.000 claims 6
- 208000004296 neuralgia Diseases 0.000 claims 6
- 230000004770 neurodegeneration Effects 0.000 claims 6
- 208000015122 neurodegenerative disease Diseases 0.000 claims 6
- 230000000926 neurological effect Effects 0.000 claims 6
- 208000021722 neuropathic pain Diseases 0.000 claims 6
- 238000000034 method Methods 0.000 claims 5
- 208000024172 Cardiovascular disease Diseases 0.000 claims 4
- 208000029027 Musculoskeletal and connective tissue disease Diseases 0.000 claims 4
- 201000011510 cancer Diseases 0.000 claims 4
- 230000002496 gastric effect Effects 0.000 claims 4
- 208000027866 inflammatory disease Diseases 0.000 claims 4
- 208000030159 metabolic disease Diseases 0.000 claims 4
- 206010033675 panniculitis Diseases 0.000 claims 4
- 208000019116 sleep disease Diseases 0.000 claims 4
- 210000004304 subcutaneous tissue Anatomy 0.000 claims 4
- 239000012472 biological sample Substances 0.000 claims 3
- -1 carboxylate anion Chemical class 0.000 claims 3
- 238000001727 in vivo Methods 0.000 claims 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims 3
- 230000001939 inductive effect Effects 0.000 claims 2
- 159000000000 sodium salts Chemical group 0.000 claims 2
- 238000011321 prophylaxis Methods 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ES202030070A ES2846824B2 (es) | 2020-01-29 | 2020-01-29 | Profarmacos de acidos grasos poliinsaturados y usos medicos de los mismos |
| ESP202030070 | 2020-01-29 | ||
| EP20382145 | 2020-02-28 | ||
| EP20382145.9 | 2020-02-28 | ||
| ES202031155A ES2911474B2 (es) | 2020-11-17 | 2020-11-17 | Profarmacos de acidos grasos monoinsaturados y sus metabolitos: usos medicos y como biomarcadores |
| ESP202031155 | 2020-11-17 | ||
| PCT/ES2021/070068 WO2021152201A2 (es) | 2020-01-29 | 2021-01-28 | Metabolitos de ácidos grasos alfa-hidroxilados, usos médicos de los mismos y uso como biomarcadores |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023518640A JP2023518640A (ja) | 2023-05-08 |
| JPWO2021152201A5 true JPWO2021152201A5 (ru) | 2024-02-05 |
Family
ID=77078835
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022542038A Pending JP2023518640A (ja) | 2020-01-29 | 2021-01-28 | αヒドロキシル化脂肪酸代謝産物、その医学的使用およびバイオマーカーとしての使用 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20230097753A1 (ru) |
| EP (1) | EP4098649A4 (ru) |
| JP (1) | JP2023518640A (ru) |
| KR (1) | KR20220132552A (ru) |
| CN (1) | CN115052852A (ru) |
| AU (2) | AU2021212330A1 (ru) |
| BR (1) | BR112022015172A2 (ru) |
| CA (2) | CA3166307C (ru) |
| CL (1) | CL2022001985A1 (ru) |
| IL (1) | IL295120A (ru) |
| MX (1) | MX2022009035A (ru) |
| WO (1) | WO2021152201A2 (ru) |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE1195296B (de) * | 1958-06-28 | 1965-06-24 | Dr Gernot Grimmer | Verfahren zur Herstellung von entzuendungs- und oedemhemmenden Salzen der cis-9-Pentadecensaeure und der cis-9-Heptadecensaeure |
| US5856537A (en) | 1996-06-26 | 1999-01-05 | The Scripps Research Institute | Inhibitors of oleamide hydrolase |
| GB9901809D0 (en) * | 1999-01-27 | 1999-03-17 | Scarista Limited | Highly purified ethgyl epa and other epa derivatives for psychiatric and neurological disorderes |
| ES2342997B1 (es) * | 2008-12-09 | 2011-06-06 | Universitat De Les Illes Balears | Alpha derivados de acidos grasos cis-monoinsaturados para ser usados como medicamento. |
| ES2345241B1 (es) * | 2009-03-16 | 2011-09-08 | Lipopharma Therapeutics | Uso de 2-hidroxiderivados de acidos grasos poliinsaturados como medicamentos. |
| EP2435057A4 (en) * | 2009-05-29 | 2012-11-28 | New Chapter Inc | COMPOSITIONS AND METHODS FOR MODULATING THE LIPID COMPOSITION |
| ES2401629B1 (es) * | 2011-10-07 | 2014-03-04 | Universitat De Les Illes Balears | Enantiómeros de 2-hidroxiderivados de ácidos grasos y su uso como medicamentos. |
| US20150173410A1 (en) * | 2013-12-19 | 2015-06-25 | Change Cola, Inc. | Beverage comprising omega fatty acid |
| JP2016222590A (ja) * | 2015-05-29 | 2016-12-28 | 国立大学法人東京海洋大学 | 脂肪酸の同位体標識化合物の製造方法およびその方法により得られた脂肪酸の同位体標識化合物、ならびに診断薬 |
-
2021
- 2021-01-28 KR KR1020227027634A patent/KR20220132552A/ko active Search and Examination
- 2021-01-28 CA CA3166307A patent/CA3166307C/en active Active
- 2021-01-28 CA CA3233141A patent/CA3233141A1/en active Pending
- 2021-01-28 WO PCT/ES2021/070068 patent/WO2021152201A2/es unknown
- 2021-01-28 EP EP21748005.2A patent/EP4098649A4/en active Pending
- 2021-01-28 JP JP2022542038A patent/JP2023518640A/ja active Pending
- 2021-01-28 MX MX2022009035A patent/MX2022009035A/es unknown
- 2021-01-28 IL IL295120A patent/IL295120A/en unknown
- 2021-01-28 US US17/759,782 patent/US20230097753A1/en active Pending
- 2021-01-28 AU AU2021212330A patent/AU2021212330A1/en not_active Abandoned
- 2021-01-28 BR BR112022015172A patent/BR112022015172A2/pt unknown
- 2021-01-28 CN CN202180011594.4A patent/CN115052852A/zh active Pending
-
2022
- 2022-07-21 CL CL2022001985A patent/CL2022001985A1/es unknown
-
2023
- 2023-10-13 AU AU2023248158A patent/AU2023248158A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2019226257B2 (en) | Use of derivatives of polyunsaturated fatty acids as medicaments | |
| JP2020519661A5 (ru) | ||
| RU99121849A (ru) | Терапевтические композиции | |
| RU2009117589A (ru) | ПРОИЗВОДНЫЕ ГИДРОБЕНЗАМИДА В КАЧЕСТВЕ ИНГИБИТОРОВ Hsp90 | |
| CA3084728A1 (en) | Fatty acid derivatives for treating non-alcoholic steatohepatitis | |
| DE69722258T2 (de) | Neue verbindungen nutlich als neuroschützende mittel | |
| AU2021204406A1 (en) | Use of structurally enhanced fatty acids containing sulphur for preventing and/or treating non-alcoholic steatohepatitis | |
| RU2749189C2 (ru) | Композиции и способы лечения ксеростомии | |
| JP3831431B2 (ja) | Ｌ−カルニチン塩および化粧用および皮膚病処置用医薬組成物 | |
| KR20210116517A (ko) | 케타민 파모에이트 및 이의 용도 | |
| KR102567090B1 (ko) | 곰팡이 감염의 치료를 위한 조성물 및 방법 | |
| US20180110747A1 (en) | Use of thia oxo compounds for lowering apo c3 | |
| JP5423905B2 (ja) | 新規化合物及びその医薬用途 | |
| JPWO2021152201A5 (ru) | ||
| JP2019535795A (ja) | 口腔感染症の処置のための組成物及び方法 | |
| EP3592351A1 (en) | 1-piperidinepropionic acid for treating a fibrosing disease | |
| JP2012520274A (ja) | 必須脂肪酸化合物 | |
| TWI555528B (zh) | 泛醇基二十二碳六烯酸酯及其於治療與預防心血管疾病的用途 | |
| JP7417595B2 (ja) | てんかん重積状態の予防、軽減又は治療のためのカルバメート化合物の使用 | |
| JP4880477B2 (ja) | 胃粘膜疾患の治療のための医薬組成物 | |
| JP7341916B2 (ja) | アポｃ３を低下させるためのチアオキソ化合物の使用 | |
| CN104262302A (zh) | L-抗坏血酸-6-(e-2-癸烯酸)酯或其衍生物以及它们的应用 | |
| JPH0840902A (ja) | 末梢神経障害および中枢神経変性疾患の治療に有用な医薬組成物 | |
| WO2023187839A1 (en) | A novel nutraceutical/therapeutical composition of cinnamic acid derivatives with sucrose isomers | |
| JPWO2020023324A5 (ru) |